Redeye: Sdiptech - Allocating capital efficiently
Redeye retains its positive view of Sdiptech following a stable Q4 report. We are encouraged by the steps Sdiptech has taken to allocate its capital to areas offering higher future returns both organically and through acquisitions. We keep our base case fair value per share intact and views stable quarterly reports along with acquisitions to be primary catalysts for the depressed share price.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/